stockrowHaleon PLC Sponsored ADR
HLN Healthcare Drug Manufacturers Specialty & Generic
Haleon PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $14.5 billion, up 1.33% from fiscal 2024.
Follow HLN
Alert me
Haleon PLC Sponsored ADR (HLN) Net margin
Haleon PLC Sponsored ADR's net margin over the twelve months to 30 September 2024 was 11.2%. Over the past ten years it has ranged from 7.72% (fiscal 2019) to 15.1% (fiscal 2025) — the current reading is the highest in ten years. That is above the Drug Manufacturers Specialty & Generic industry median of −2.45% and above the Healthcare sector median of 0.00%.
Net margin, annual
Embed this chart
Annual newest first
| Period | Net margin | Change (points) |
|---|---|---|
| FY2025 | 15.1% | 2.27 |
| FY2024 | 12.8% | 3.56 |
| FY2023 | 9.28% | (0.48) |
| FY2022 | 9.76% | (4.80) |
| FY2021 | 14.6% | 2.98 |
| FY2020 | 11.6% | 3.86 |
| FY2019 | 7.72% | — |
Quarterly newest first
| Period | Net margin | Change (points) |
|---|---|---|
| Sep 2024 | 17.5% | 2.96 |
| Mar 2024 | 14.5% | 1.44 |
| Sep 2023 | 13.1% | 7.58 |
| Jun 2023 | 5.47% | (7.56) |
| 1 more quarters | Free account |
Against its own ten years
Net margin against peers
| Company | Net margin |
|---|---|
| UTHR United Therapeutics Corporation compare | 38.6% |
| ZTS Zoetis Inc. compare | 27.7% |
| NBIX Neurocrine Biosciences, Inc. compare | 19.0% |
| HLN Haleon PLC Sponsored ADR | 11.2% |
| RDY Dr. Reddy's Laboratories Ltd compare | 8.06% |
| TAK Takeda Pharmaceutical Co. compare | 7.12% |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 2.94% |
| ELAN Elanco Animal Health Incorporated compare | −3.96% |
| VTRS Viatris Inc. compare | −4.13% |
| Drug Manufacturers Specialty & Generic industry median | −2.45% |
| Healthcare sector median | 0.00% |
| Market median | 1.06% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue
More on HLN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- Beneish M-score
- The full statement